Perindopril Erbumine Research Articles

Microchip isotachophoresis for green and sustainable pharmaceutical quality control: Method validation and application to complex pharmaceutical formulations

Universal microchip isotachophoresis (μITP) methods were developed for the determination of cationic and anionic macrocomponents (active pharmaceutical ingredients and counterions) in cardiovascular drugs marketed in salt form, amlodipine besylate and perindopril erbumine. The developed methods are characterized by low reagent and sample consumption, waste production and energy consumption, require only minimal sample preparation and provide fast analysis. The greenness of the proposed methods was assessed using AGREE. An internal standard addition was used to improve the quantitative parameters of μITP. The proposed methods were validated according to the ICH guideline. Linearity, precision, accuracy and specificity were evaluated for each of the studied analytes and all set validation criteria were met. Good linearity was observed in the presence of matrix and in the absence of matrix, with a correlation coefficient of at least 0.9993. The developed methods allowed precise and accurate determination of the studied analytes, the RSD of the quantitative and qualitative parameters were less than 1.5% and the recoveries ranged from 98 to 102%. The developed μITP methods were successfully applied to the determination of cationic and anionic macrocomponents in six commercially available pharmaceutical formulations.

Fabrication of pH-responsive hydrogels of perindopril erbumine using black seed extract and β-cyclodextrin co-polymerized with methacrylic acid and methylene bisacrylamide

Fabrication of pH-responsive hydrogels of perindopril erbumine using black seed extract and β-cyclodextrin co-polymerized with methacrylic acid and methylene bisacrylamide

Development and Validation of Chemometric Assisted RP-HPLC Method for Simultaneous Estimation of Perindopril Erbumine, Indapamide, and Amlodipine Besylate in Bulk and Pharmaceutical Formulation

This research paper illustrates a latterly developed, optimized and validated gradient RP-HPLC approach for simultaneous analysis ofIndapamide, Perindopril erbumine and Amlodipine besylate in bulk and pharmaceutical formulation with the assistance of quality by design. Qualityis predicated on desired and predetermined specifications. Understanding various factors, dependent variables, and their interconnection effectsby a desired set of experiments on the responses to be analyzed is an important component of QbD. Several operating conditions of variousprocesses optimization, chromatographic separation performance improvement, and high extraction efficiency were attained by using QbD. Thepowerful chromatographic conditions were done using the HypersilC18 column (250mm × 4.6mm, 5μm particle Size). The UV detector wasadjusted to 215nm. Design of experiments (DoE) was applied for multivariate optimization of the experimental conditions of the RP-HPLCmethod. Three independent factors, mobile phase composition, phosphate buffer strength, and flow rate, were used to design mathematicalmodels. Central composite design (CCD) was used to examine the response surface methodology and fully examine the results of theseindependent factors. The desirability function was used to optimize the retention time and resolution of the analytes simultaneously. Theimproved and anticipated data from the contour diagram consisted of methanol and phosphate buffer (pH 2.5, strength 0.05M) in the ratio of65:35, respectively, at a flow rate of 1.1 ml/min. Using these optimum conditions, baseline separation of both drugs with good resolution and runtime of less than 5.0 min was achieved. The novelty of the developed method was time-consuming, cost-effective, and sensitive. The optimizedassay conditions were validated according to ICH guidelines. Under the optimized state, the linearity ranges were found to be 10-40 μg/mL, 32–128 μg/mL, and 40-160 μg/mL for Indapamide, Perindopril erbumine, and amlodipine besylate, respectively, with correlation coefficients (R2) of0.999. The mean accuracy studied ranged from 99.18 to 99.58%. The percentage coefficient variation value for the precision study was lower than1%. The proposed method showed good precision and repeatability. Hence the developed RP-HPLC method using quality by design can be usedas a routine quality control analysis of indapamide, perindopril erbumine, and amlodipine besylate.

Development and validation of high‐performance thin layer chromatographic method for simultaneous quantitation of novel combination perindopril erbumine and moxonidine hydrochloride

AbstractThe primary purpose of the present study was to develop and validate a high‐performance thin‐layer chromatography method for quantitatively determining an anti‐hypertensive agent, perindopril erbumine, and moxonidine hydrochloride in bulk and synthetic mixture. The densitometric procedure was performed on aluminum thin‐layer chromatography plates pre‐coated with silica gel 60F254, employing a combination of dichloromethane: toluene: methanol: ammonia (7:1:2:0.1 v/v/v/v) as the mobile phase. The thin‐layer chromatography scanner was operated in absorbance mode at a wavelength of 223 nm to evaluate densitograms. The linearity of the method was established in the range of 1000–5000 ng/band for perindopril erbumine and 40–200 ng/band for moxonidine hydrochloride; the correlation coefficient (r2) was 0.9993 and 0.9983, respectively. The values of a limit of detection (186.06 and 3.51 ng/band, respectively, for perindopril erbumine and moxonidine hydrochloride) and limit of quantification (620.23 and 11.73 ng/band, respectively, for perindopril erbumine and moxonidine hydrochloride) have demonstrated the sensitivity of the developed method. The reported process was precise in both intra‐day and inter‐day analysis; the percentage relative standard deviation of peak area was less than 2% and has an accuracy within 100 ± 2%. The developed method has the potential to quantify perindopril erbumine and moxonidine hydrochloride from its synthetic mixture without any interference from other components or in quality control laboratories.

Exploration of polymethacrylate and Hypromellose for the development of a non-sulfhydryl ACE inhibitor mucoadhesive system using Box-Behnken design: in-vitro and ex-vivo evaluation

Purpose To counteract early morning pathology like hypertension a time-dependent release of the drug is required. This study is focused to formulate a pulsatile and mucoadhesive drug delivery system of an ACE inhibitor Perindopril Erbumine. Method Two matrix tablets were punched with Eudragit RSPO, Eudragit RLPO, and HPMC K15M using a 3-3-3 Box-Behnken Design of Response Surface Methodology. Based on the design-optimized formulation P1T3 and P2T8 were coated for a lag time with compression coating of HPMC K4M and a blend of 1:1 ratio of ethylcellulose and carbopol polymer and further encapsulated in a Eudracap™ capsule to provide gastric resistance. Result The in-vitro release data confirmed an initial pause phase of 4.5 h then release of the drug for 5.2 ± 0.3 h to cope with the early morning rush in blood pressure. After that, a gap of 6 h and then sustained release of the drug for 10.5 ± 0.5 h. From the ex-vivo study, mucoadhesive strength was obtained as 55.13 ± 0.03 gm and 56.39 ± 0.02 gm for P1T3 and P2T8 respectively. The lag time for coated tablet P1T3 came to 2.15 ± 0.15 h and for P2T8 11.9 ± 0.10 h proving the coating efficiency of polymers. Conclusion The current study strongly suggests that perindopril Erbumine in association with Eudragit and Hypromellose polymer can open a path for the time-regulated release of the drug for hypertension chronotherapy with less risk of dose dumping.

Development and validation of stability indicating RP-HPLC method for estimation of Perindopril Erbumine and Indapamide in bulk and pharmaceutical dosage form

Background: Perindopril erbumine (PE) and Indapamide (IND) in combination were proven to have a synergistic antihypertensive impact when compared with the use of each component alone. Objectives: Therefore, a new simple, selective, precise, and stability indicating RP- HPLC method for analysis of Perindopril erbumine (PE) and Indapamide both in a bulk and in pharmaceutical formulation has been developed and validated. Methods: RP ‑ HPLC method, Younglin (S.K.) Gradient System UV Detector and C18 column with 250mm x 4.6 mm i. d. and 5μm particle size acetonitrile 70+ water with OPA 30 was used as the mobile phase for the method. The detection wavelength was 215 nm and flow rate was 1 ml/min. Results: In the developed method, the retention time of Perindopril erbumine (PE) and Indapamide were found to be 5.4833 min and 9.4500min. The developed method was validated according to the ICH guidelines. The linearity, precision, range, robustness was within the limits as specified by the ICH guidelines. Conclusion: Hence the method was found to be simple, accurate, precise, economic and reproducible. The forced degradation studies proved stability indicating power of the method.

Combination of Perindopril Erbumine and Huangqi-Danshen Decoction Protects Against Chronic Kidney Disease via Sirtuin3/Mitochondrial Dynamics Pathway.

Background Chronic kidney disease (CKD) is a major public health problem worldwide. Treatment with renin-angiotensin system inhibitors can achieve only partial efficacy on renal function decline and renal fibrosis in CKD patients. Huangqi-Danshen decoction (HDD) is a basic Chinese herbal pair which is commonly used to treat CKD with good efficacy.Objectives The current study aimed to investigate the effect of perindopril erbumine (PE), an angiotensin-converting enzyme inhibitor, combined with HDD on adenine-induced CKD rat model and explore the possible mechanism from Sirtuin3/mitochondrial dynamics pathway Method CKD rat model was established by feeding of 0.75% w/w adenine containing diet for 3 weeks. At the same time, the treatment groups were given PE (0.42 mg/kg/d) or HDD (4.7 g/kg/d) or PE combined with HDD by gavage for 4 weeks. Renal function was evaluated by the levels of serum creatinine (Scr) and blood urea nitrogen (BUN). The renal pathological injury was observed by periodic acid-Schiff (PAS) and Masson's trichrome staining. Proteins expression was determined by Western blot analysis. Mitochondrial morphology was observed by transmission electron microscopy. Results PE in combination with HDD significantly improved renal function, reduced tubular injury and interstitial fibrosis in adenine-induced CKD rats. Moreover, PE + HDD treatment mainly activated the Sirtuin3 expression level. In addition, PE + HDD exhibited bidirectional regulation on mitochondrial dynamics by suppressing mitochondrial fission protein dynaminrelated protein 1 expression and elevating mitochondrial fusion protein optic atrophy 1 expression, resulted in restraint of mitochondrial fragmentation.Conclusion The combination of PE and HDD attenuated adenine-induced CKD in rats, which was possibly associated with Sirtuin3/mitochondrial dynamics pathway.

Exploring and modeling the ion mobility spectrometry of perindopril: Example of protonation-dissociation reactions in large molecules.

The current research is constructed for considering the chemical ionization and dissociation of perindopril in the positive mode of corona discharge ion mobility spectrometry. Four product ion peaks are observed in the ion mobility spectrum of perindopril erbumine at the cell temperature of 473 K. These peaks are assigned through the obtained intensity variation analysis in the ion mobility spectra over the elapsed time accompanied by the calculations backed by the validated density functional theory (DFT). In this regard, the most stable ionic species associated with each peak and the corresponding reliable generation pathways are found by the well-confirmed meta hybrid density functional method, M06-2X. The peaks are assigned to the protonated perindopril and its dissociation products, including counter ion and the related fragment ions. However, the structures of the neutral perindopril in the gas phase are thoroughly assessed to find a more stable one. The predicted chemical ionization products by the theory are in excellent agreement with our presented experiment here. Theoretical evaluations demonstrated that the production of a fragment by dissociation process occurs when perindopril gets a proton from the ionization region. Also, without protons, there is no dissociation process. Therefore, our mechanism investigated here is the proton transfer one. All possible sites of perindopril are considered theoretically for protonation along with their possible reactions. In addition to the computed PES, the assigned ions for obtained spectra are confirmed by the computed equilibrium constants and rate constants. Our theoretical results show that the peak of the main fragment is for M-CH3 CH2 OH produced by a reaction pathway involving no barrier. This study opens new perspectives in interpreting large molecules spectra for future studies.

Determination of perindopril erbumine by oxidative coupling reaction using 2, 6-dichloroquinone-4-chlorimide

Perindopril erbumine (Perindopril tert-butylamine salt) is a potent angiotensin-converting enzyme (ACE) inhibitor. It is used to treat the patients with hypertension and heart failure problems. A sensitive, inexpensive and precise analytical technique has been developed for the estimation of perindopril in bulk and formulations. The procedure involves the development of colour by forming an oxidative coupling reaction between drug (PPE) and reagent such as 2, 6-dichloroquinone-4-chlorimide (DCQC). The formed colored species were measured at (max=520 nm. The developed method showed linearity within the concentration limits of 25-75 μg mL-1. The linear correlation coefficient (r) and molar absorptivity were found to be 0.9999 and 3.285 x 103 mol-1cm-1. % Recovery ± SD values were in the range of 99.69 - 100.51 (+ 0.42 - ( 0.41) (n=3) which indicates the accuracy of the developed method. The interference of other excipients that are commonly present in formulations is found to be negligible. Precision and accuracy of the proposed method were confirmed by student t-test and F-tests at 95% confidence limits with (n-1) degrees of freedom. The validity parameters of proposed method were calculated by ICH guidelines.

Jian-Pi-Yi-Shen formula enhances perindopril inhibition of chronic kidney disease progression by activation of SIRT3, modulation of mitochondrial dynamics, and antioxidant effects.

Chronic kidney disease (CKD) is a global public health problem. Renin–angiotensin system (RAS) blockade is the mainstay of CKD therapy with limitations. Jian-Pi-Yi-Shen formula (JPYSF) is a traditional herbal decoction and has been used for treating CKD for decades. The purpose of the present study was to investigate the intervention effects of combined used of perindopril erbumine (PE) and JPYSF on CKD progression and explore their underlying mechanisms. CKD rat model was induced by feeding a diet containing 0.75% w/w adenine for 3 weeks. CKD rats were treated with PE or JPYSF or PE+JPYSF from the induction of CKD and lasted 4 weeks. Renal function was evaluated by serum creatinine (Scr) and blood urea nitrogen (BUN). Pathological lesions were observed by Periodic acid–Schiff (PAS) and Masson’s trichrome staining. The protein expression was tested by Western blot and immunohistochemistry analysis. The morphology of mitochondria was observed by transmission electron microscope. The results showed that combined used of PE and JPYSF could better improve renal function and pathological lesions and ameliorate renal fibrosis in CKD rats. Administration of PE and JPYSF enhanced sirtuin 3 (SIRT3) expression, inhibited mitochondrial fission, promoted mitochondrial fusion, and suppressed oxidative stress in the kidney of CKD rats. In conclusion, combined use of PE and JPYSF protected against CKD more effectively than either alone. The underlying mechanism may be associated with activation of SIRT3, modulation of mitochondrial dynamics, and antioxidant effects.

Application of Oxidative Coupling Reaction using Brucine and Sodium Periodate as Chromogenic Reagent for the Assay of Perindopril Erbumine in Formulations

The drug Perindopril Erbumine (PE), an ACE inhibitor, and can be used to treat the patients with hypertension and cardiac failure problems. A sensitive, inexpensive, and precise analytical technique has been developed for the estimation of Perindopril in bulk and formulations. The procedure involves the development of color by forming an oxidative coupling reaction between drug (PE) and Brucine/IO4-). The formed colored species were measured at max=520 nm. The developed method showed linearity within the concentration limits of 8-24 μg mL-1. The linear correlation coefficient (r) and molar absorptivity were found to be 0.9999 and 9.16 x 103 mol-1.cm-1. % Recovery ± SD values were in the range of 99.16 - 100.7 (± 0.41 - ± 0.8) (n=3) which indicates the accuracy of the developed method. The interference of other excipients that are commonly present in formulations is found to be negligible. Precision and accuracy of the proposed method were confirmed by Student’s t-test and F-tests at 95% confidence limits with (n-1) degrees of freedom. The validity parameters of the proposed method were calculated by ICH guidelines.

Spontaneous Rapid Improvement of Small Intestinal Edema

Question: A 69-year-old woman was admitted to our hospital because of sudden abdominal pain and vomiting. She had a history of IgA nephropathy, hypertension, lipid metabolism abnormality, and cholelithiasis. She had been taking perindopril erbumine and pitavastatin calcium for hypertension. On presentation, she had a mild tenderness in the lower abdomen but no sign of peritoneal irritation or fever.

Direct Spectrophotometric Determination of Perindopril Erbumine and Enalapril Maleate in Pure and Pharmaceutical Dosage Forms using Bromocresol Green

In this article, it has been reported new, simple, sensitive and direct spectrophotometric methods for the determination of Perindopril Erbumine (PPE) and Enalapril Maleate (ENL) in pure and in pharmaceutical forms. Spectrophotometric methods are based on the formation of yellow colored ion-pair complexes between PPE, ENL and sulphonphthalein acid dye, Bromocresol green (BCG) into chloroform were measured at the wavelength of 414 and 415nm for PPE and ENL, respectively. The optimal analytical conditions were determined. The obtained complexes (BCG: PPE) and (BCG: ENL) reached maximum absorbance directly after formation at room temperature for a stability period of 24 h. Beer’s law were obeyed in the concentration ranges of (2-20)µg/mL for PPE and (8- 44)µg/mL for ENL, the limit of detection of 0.125μg/mL and 0.230μg/mL were found for PPE and ENL, respectively. The molar absorptivity coefficients were 4.4045*104 L.moL-1.cm-1 for PPE and 1,9330*104 L.moL-1.cm-1 for ENL. The stoichiometry of the complexes formed between PPE, ENL and BCG were 1:1. No interference was observed from common excipients occurred in pharmaceutical formulations and the proposed methods have been successfully applied to determine the PPE and ENL in some pharmaceutical products and in ENL combination dosage forms with hydrochlorothiazide (HCTZ). The proposed methods were successfully validated to be utilized in the quantitative analysis of PPE and ENL in their pure and pharmaceutical products. A good agreement between the developed spectrophotometric methods with the results obtained from official reference methods for the determination of the two drugs in some real samples demonstrate that the proposed methods were suitable to quantify PPE and ENL in pharmaceutical formulations.

Analytical Techniques for the Estimation of Perindopril Erbumine: A Review

This paper includes different analytical methods available for the estimation of the Perindopril Erbumine. Perindopril Erbumine is an Angiotensin-Converting Enzyme (ACE) inhibitor used to treat hypertension and heart failure. The drug is officially listed in the monograph of USP, BP & EP. This drug is available in various marketed formulations. There are so many methods reported for the estimation of Perindopril Erbumine and its related substances. Various methods including UVspectroscopic method, stability-indicating liquid chromatography method, Thermo-Radio, and Photostability study, Stability indicating UHPLC-DAD method, LC-MS/MS electrospray ionization validated method, and LC-MS/MS bioanalytical method are discussed in this paper.

A new RP\u2013HPLC method for simultaneous quantification of perindopril erbumine, indapamide, and amlodipine besylate in bulk and pharmaceutical dosage form

BackgroundPerindopril erbumine is a specific inhibitor of angiotensin-converting enzyme, indapamide is the one providing thiazide diuretic effect, and amlodipine besylate is a calcium antagonist which belongs to the dihydropyridines which helps to maintain the pressure of the blood in the patient having arterial hypertension. The literature survey discloses that only one method is available for the estimation of the combination in the quantitative analytical liquid chromatographic method. Moreover to this, the literature review also reveals that HPTLC, UV spectroscopy, and HPLC methods are available for the analysis of either of the two in combination. Hence, our area of interest is to develop and validate the RP-HPLC in order to quantify perindopril erbumine, indapamide, and amlodipine besylate simultaneously in bulk and formulation.ResultSensitive and accurate RP-HPLC method was developed for the simultaneous estimation of indapamide, perindopril erbumine, and amlodipine besylate in bulk and available as triplixam-marketed tablet dosage form which is a combination of these drugs. The Phenomenex C-18 column (250 mm × 4.6 mm, 5 μm) was used as a stationary phase, and acetonitrile: methanol: water (30:20:50, v/v/v) was found to be optimized mobile phase which was further adjusted to pH 3.0 by utilizing 1.0% orthophosphoric acid; the flow rate kept was 1 ml/min and experiments were performed using PDA detector. The common detection wavelength for all the three APIs was found to be 215.0 nm. The method was validated as per ICH Q2 (R1). The linearity range for amlodipine besylate was found to be 0.500–9.500 μg/ml; for perindopril erbumine was found to be 0.400–7.600 μg/ml, and for indapamide was found to be 0.125–2.375 μg/ml. The correlation coefficient was found to be more than 0.9975 for all three of them, whereas the mean percentage recovery was found to be 99.52–100.71%, 99.49–100.89%, and 99.90–100.78%, respectively.ConclusionThe proposed RP-HPLC method is found to be accurate and robust enough to estimate the perindopril erbumine, indapamide, and amlodipine besylate simultaneously in bulk and available tablet dosage form of combination.

Rosuvastatin, Perindopril and Ezetimibe loaded instant release buccal films: Development and in vitro characterization.

Rosuvastatin Calcium and Ezetimibe are used to control cholesterol level while Perindopril Erbumine is used to treat hypertension. Hepatic metabolism reduces the therapeutic effect of these drugs. Instant release buccal films (IRBFs) could possibly be a solution to this issue. The objective of the study was to formulate IRBFs of Rosuvastatin Calcium, Perindopril Erbumine and Ezetimibe using solvent casting technique. Polymers used to prepare IRBFs included hydroxypropyl methylcellulose (HPMC E5), PEG 400 (as plasticizer) and Tween 80 (as surfactant). Solvent casting technique was used to fabricate the films, followed by their in-vitro analysis including high performance liquid chromatography (HPLC), X-ray diffraction (XRD), fourier transform infrared evaluation (FTIR), In-vitro dissolution, In-vitro disintegration, stability tests, scanning electron microscopy (SEM), folding fortitude, thickness evaluation, surface pH, tensile strength, weight variation and percentage moisture content. Optical microscopy as well as SEM analysis displayed that the surfaces of IRBFs were smooth with uniform mixing of ingredients. IRBFs disintegrated within 15 seconds while on dissolution they exhibited instant drug release i.e. 100% release in 2 minutes. The results show promising potential of IRBFs in drug delivery.

Back Cover: Simultaneous quantification of perindopril erbumine, indapamide and amlodipine besylate in newer combination of anti‐hypertensive drugs in pharmaceutical dosage form by thin layer chromatography method

DOI: 10.1002/sscp.202000010 The cover picture shows the HPTLC method developed for the simultaneous identification and quantification of Perindopril erbumine, Indapamide and Amlodipine besylate in bulk and pharmaceutical dosage form. According to ICH guidelines the method was validated and found to be sensitive, accurate and precise. Statistical analysis proved that method was repeatable and selective for the analysis of Perindopril erbumine, Indapamide and Amlodipine besylate without any interference from the excipients. The method was successfully used for the determination of drug in their pharmaceutical formulation.

Functionalized crosslinked interpenetrating polymeric network for pH responsive colonic drug delivery

Current exploration unveils the promising role of arabinoxylan (AX) in targeted delivery of acid labile active moiety, by using methacrylic acid (MAA) as monomer, N′,N′-methylene-bis-acrylamide (MBA) as crosslinker and ammonium persulfate as initiator. Different feed composition of AX, MAA and MBA was blended to optimize hydrogels by free radical polymerization technique. Formulation AXMA2 showed maximum swelling and drug release at pH 7.4. Fourier transform infrared spectroscopy (FTIR) depicts crosslinking of MAA and AX based. Thermal characterization confirmed the formation of thermodynamically stable hybrid. However, morphological studies showed porous architecture. The pH sensitivity of hydrogels has been affirmed by swelling dynamics, equilibrium swelling ratio (ESR), on–off switching and drug release studies in acidic and alkaline pH. Drug release studies showed controlled release of the perindopril erbumine from polymeric network. Crosslinked AX nexus can be used as promising carrier for the configuring and formulating targeted drug-delivery systems.

Simultaneous quantification of perindopril erbumine, indapamide and amlodipine besylate in newer combination of anti‐hypertensive drugs in pharmaceutical dosage form by thin layer chromatography method

AbstractA sensitive, precise, robust and accurate high performance thin layer chromatographic method was developed and validated base on ICH Q2 (R1) guideline for the simultaneous estimation of Perindopril erbumine, Indapamide and Amlodipine besylate in bulk and combined Triplixam marketed tablet dosage formulation. Pre‐coated silica gel aluminum plate 60 F254 was selected as the stationary phase and dichloromethane: methanol: toluene: glacial acetic acid (7: 1: 2: 0.1, v/v/v/v) was used as developing mobile phase. The common detection wavelength for Perindopril erbumine, Indapamide and Amlodipine besylate was carried out at 215 nm. The method was validated for linearity, precision, accuracy, and robustness, limit of detection and limit of quantitation as per ICH parameters. The correlation coefficient (r2) of Perindopril erbumine, Indapamide and Amlodipine besylate were found to be 0.9987, 0.9987 and 0.9996, respectively. The mean of percentage recovery of Perindopril erbumine, Indapamide and Amlodipine besylate were found to be 99.38‐101.81, 100.61‐102.68 and 99.87‐101.95%, respectively. The proposed thin layer chromatography method has potential qualitative as well as quantitative applications for simultaneous estimation of Perindopril erbumine, Indapamide and amlodipine besylate in bulk and pharmaceutical dosage form.

Method Development and Validation for the Analysis of Perindopril Erbumine and Amlodipine Besylate by RP-HPLC in Pure and Pharmaceutical Dosage Form

Method Development and Validation for the Analysis of Perindopril Erbumine and Amlodipine Besylate by RP-HPLC in Pure and Pharmaceutical Dosage Form